Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
-
Clinical Trial Information
Trial Contact: Cevallos, Claudia; El-Shami, Jessica; Leffin, Melissa; Spinelli, Jennifer
Trial Phone: 321-841-7561 ; 321.841.3837 ; 321.841.2008 ; 321.841.5357
-
IRB No: APEC1621B
Protocol Abbrev: APEC1621B
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621B
Treatment: Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03210714
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with JNJ-42756493 (erdafitinib) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4 pathway
-
Key Eligibility
Sexes Eligible for Study - All
Ages - 12 Months to 21 Years (Child, Adult)
Accepts Healthy Volunteers - No
